Dark

SCPH
scPharmaceuticals Inc. Common Stock
stock NASDAQ

At Close

May 16, 2025 3:59:30 PM EDT

3.22USD+11.806%(+0.34)1,201,485

2.78Bid 3.34Ask 0.56Spread

Pre-market

May 16, 2025 9:27:30 AM EDT

2.93USD+1.736%(+0.05)1,352

After-hours

May 16, 2025 4:00:30 PM EDT

3.22USD0.000%(0.00)365

OverviewOptionsHistoricalExchangesShortsNews

Dec 20, 2021

04:05PM EST scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, president & chief executive officer, will participate virtually in two upcoming investor conferences. GlobeNewswire Inc

Nov 9, 2021

11:33AM EST scPharmaceuticals Q3 EPS $(0.24) Up From $(0.33) YoY Benzinga

07:00AM EST All additional testing of devices manufactured on the planned commercial line, as required by the FDA, has been successful to date GlobeNewswire Inc

Nov 2, 2021

08:30AM EDT scPharmaceuticals to Present at the Jefferies London Healthcare GlobeNewswire Inc

Sep 10, 2021

08:12AM EDT scPharmaceuticals Inc. Highlights Presentation Of Late-Breaking FREEDOM-HF Study Data At The Heart Failure Society Of America Annual Scientific Meeting 2021 Benzinga

08:00AM EDT Data show statistically significant and meaningful reduction in both heart failure-related and overall healthcare costs for patients treated with FUROSCIX versus a historical comparator group GlobeNewswire Inc

Sep 9, 2021

11:05AM EDT Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2021 Benzinga

06:26AM EDT SVB Leerink Initiates Coverage On scPharmaceuticals with Market Perform Rating, Announces Price Target of $6 Benzinga

Sep 1, 2021

08:00AM EDT scPharmaceuticals to Present at the Virtual H.C. Wainwright 23rd GlobeNewswire Inc

Aug 19, 2021

10:57AM EDT The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck Benzinga

Aug 18, 2021

07:38AM EDT The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline Benzinga

Aug 11, 2021

07:40AM EDT scPharmaceuticals Q2 EPS $(0.26) Up From $(0.36) YoY Benzinga

07:00AM EDT Received minutes from Type C meeting with the FDA confirming alignment on path toward resubmission of FUROSCIX NDA; no additional clinical data or device modifications required at this time; on track for resubmission in Q4 GlobeNewswire Inc

Jul 14, 2021

07:48AM EDT The Daily Biotech Pulse: ScPharma's Positive Data, Lilly Goes Shopping, LeMaitre Pre-Announces Q2 Revenues Benzinga

06:28AM EDT scPharma's Furoscix Can Potentially Cut Hospital Admission/Readmission Costs For Heart Failure Patients Benzinga

Jul 13, 2021

04:13PM EDT scPharmaceuticals Says Study Halted Early Due To Highly Statistically Significant Reduction In 30-day Heart Failure-related Costs Observed During The Prespecified Interim Analysis Benzinga

04:13PM EDT scPharmaceuticals Inc. Announces Mean Difference In Heart Failure-Related Costs Between Two Groups Was $17,753 Per STudy Subject Benzinga

04:11PM EDT scPharmaceuticals Inc. Announces Top-Line Results From FREEDOM-HF Study Benzinga

04:09PM EDT Reduced average 30-day heart failure related costs by $17,753 (p<0.0001) per study subject in FUROSCIX arm compared to historically matched comparators GlobeNewswire Inc

Jul 1, 2021

08:04AM EDT UPDATE: scPharma Says FORSCIX New Drug Application Resubmission Targeted For Q4'21 Benzinga

08:04AM EDT UPDATE: scPharma Says No Added Clinical Data, Device Modifications For Its FUROSCIX Required At This Time Benzinga

08:04AM EDT scPharma Reports Receipt Of Written Minutes From Type-C Meeting With FDA Related To Development Of FUROSCIX Benzinga

08:00AM EDT scPharmaceuticals Inc. Announces Receipt of Written Minutes from GlobeNewswire Inc

May 19, 2021

08:00AM EDT scPharmaceuticals to Present at the Jefferies Virtual Healthcare GlobeNewswire Inc

May 12, 2021

08:06AM EDT scPharmaceuticals Q1 EPS $(0.26) Up From $(0.35) YoY Benzinga

08:00AM EDT scPharmaceuticals Inc. Reports First Quarter 2021 Financial GlobeNewswire Inc

Mar 23, 2021

08:18AM EDT The Daily Biotech Pulse: FDA Approvals For Merck, Pacira And Zealand, Roche-Regeneron Ace Late-Stage COVID-19 Study, AlloVir Appoints Gilead Virology Chief As CEO Benzinga

07:10AM EDT scPharmaceuticals Q4 EPS $(0.28) Up From $(0.58) YoY Benzinga

07:00AM EDT scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2020 GlobeNewswire Inc

Feb 25, 2021

08:00AM EST scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, president & chief executive officer, will participate in two upcoming investor conferences. GlobeNewswire Inc

Feb 23, 2021

11:03AM EST ScPharmaceuticals Sees US Application Submission For Furoscix In Q3 Benzinga

08:02AM EST scPharmaceuticals Inc. Announces Results Of Type A End-Of-Review Meeting With FDA Regarding FUROSCIX ND; No Additional Clinical Efficacy, PK Or Safety Data Required Benzinga

08:00AM EST scPharmaceuticals Inc. Announces Results of Type A End-of-Review GlobeNewswire Inc

Feb 17, 2021

08:00AM EST scPharmaceuticals Inc. Appoints Renowned Heart Failure Specialist GlobeNewswire Inc

Feb 11, 2021

08:00AM EST scPharmaceuticals to Present at the 10th Annual SVB Leerink Global GlobeNewswire Inc

Dec 10, 2020

02:19AM EST SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of PR Newswire

Dec 7, 2020

02:55PM EST Mid-Afternoon Market Update: Dow Tumbles 180 Points; Eastman Kodak Shares Spike Higher Benzinga

12:18PM EST Mid-Day Market Update: Gold Rises 1.5%; Lyra Therapeutics Shares Plunge Benzinga

10:10AM EST Mid-Morning Market Update: Markets Open Mostly Lower; Seacor Holdings To Go Private Benzinga

08:21AM EST scPharmaceuticals Says 'In addition, the FDA indicated that there were deficiencies at the third-party facility where the Company's off-the-shelf alcohol swabs are manufactured.' Benzinga

08:20AM EST scPharmaceuticals Also Says 'FDA raised questions related to testing, labeling, and features of the combination product unrelated to the drug constituent' Benzinga

08:20AM EST scPharmaceuticals Says 'In the CRL, the FDA cited their need to conduct pre-approval inspections at two of the company's third-party manufacturing facilities that could not be conducted due to travel restrictions.' Benzinga

08:19AM EST scPharmaceuticals Inc. Receives Complete Response Letter From FDA For FUROSCIX Benzinga

08:15AM EST ScPharmaceuticals Receives Complete Response Letter Regarding NDA For FUROSCIX RTTNews

08:00AM EST scPharmaceuticals Inc. Receives Complete Response Letter from FDA GlobeNewswire Inc

Nov 30, 2020

06:11AM EST SVB Leerink Maintains Market Perform on scPharmaceuticals, Raises Price Target to $12 Benzinga

Nov 28, 2020

01:08PM EST Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates Benzinga

Nov 19, 2020

08:00AM EST scPharmaceuticals to Present at the 3rd Annual Evercore ISI GlobeNewswire Inc

Nov 16, 2020

07:08AM EST scPharmaceuticals Q3 EPS $(0.33), Same YoY Benzinga

07:00AM EST Commercialization preparedness activities continuing ahead of December 30 PDUFA date for FUROSCIX (furosemide injection) for subcutaneous administration GlobeNewswire Inc

Nov 11, 2020

08:00AM EST scPharmaceuticals to Present at the Jefferies Virtual London GlobeNewswire Inc

Oct 8, 2020

08:09AM EDT scPharmaceuticals Provides Business Update Benzinga

Sep 17, 2020

08:00AM EDT scPharmaceuticals Hosting Key Opinion Leader Call on FUROSCIX(r) (furosemide) for subcutaneous administration Business Wire

Sep 3, 2020

08:00AM EDT scPharmaceuticals to Participate in Two Upcoming Investor Conferences Business Wire

Aug 13, 2020

07:18AM EDT scPharmaceuticals Q2 EPS $(0.39), Same YoY Benzinga

07:13AM EDT ScPharmaceuticals Inc. Q2 Net Loss $8.3 Mln Vs. Net Loss $7.3 Mln Last Year RTTNews

07:00AM EDT scPharmaceuticals Inc. Reports Second Quarter 2020 Financial Results and Provides Business Update Business Wire

Jul 27, 2020

08:11AM EDT scPharmaceuticals Announces FDA Acceptance Of FUROSCIX New Drug Application Resubmission; FDA Sets PDUFA Date Of December 30, 2020 Benzinga

08:05AM EDT ScPharmaceuticals: FDA Accepts For Review NDA Resubmission For FUROSCIX RTTNews

08:00AM EDT scPharmaceuticals Announces FDA Acceptance of FUROSCIX(r) New Drug Application Resubmission Business Wire